Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Other strategies for ferroptosis In addition
2021-09-17

Other strategies for ferroptosis In addition to ROS-generating and GPX4 inactivating nanomaterials, small molecules and genetic manipulation targeting key factors in the ferroptosis pathway have also been tested for their anticancer effects [39,47,48]. Among a myriad of proteins involved in ferro
-
Thus aldolase catalyzing the reversible reaction of F P
2021-09-17

Thus, aldolase catalyzing the reversible reaction of F1,6-P2 synthesis is involved in the formation of the glyconeogenic or glycolytic complex, dependently on the physiological state of the cell. In the process of glycogen synthesis, the enzyme not only supplies the substrate for FBPase and desensit
-
br Role of funding source br Conflict of
2021-09-17

Role of funding source Conflict of interest Acknowledgements We thank F. Blaskovits and P. Kesner for technical assistance. This project was supported by operating grants from the Canadian Institutes of Health Research (CIHR) to X. Zhang (MOP123249) and the National Natural Science Foundati
-
We found the FAAH CC
2021-09-17

We found the FAAH CC genotype only confers risk for anxiety if the CRFR1 minor allele combination is also present. Additionally, the FAAH AA/AC genotype was riskier than the CC if the three CRFR1 minor CCT251545 analogue were not present. This result is somewhat contrary to our prediction as we hyp
-
pevonedistat australia br Introduction The period around bir
2021-09-17

Introduction The period around birth is a risky time for stroke in infants. Ischemic stroke has been diagnosed in about 1/4000 full-term infants (Nelson and Lynch, 2004) and perinatal stroke represents the second most frequent cause of acute seizures in this age group (Levy et al., 1985). Further
-
Betahistine N methyl pyridyl ethylamine is a well
2021-09-16

Betahistine (N-methyl-2-(2-pyridyl)ethylamine) is a well-known dual H1 Psalmotoxin 1 agonist/H3 receptor antagonist with structural resemblance to histamine. Though it has been approved long before the discovery of H3R to treat disorders of vestibular function as Menières-Disease, the evidence for
-
Since its development the HCV replicon system Lohmann
2021-09-16

Since its development, the HCV replicon system (Lohmann et al., 1999) has been a critical tool in the HCV antiviral discovery process (Gottwein et al., 2009, Imhof and Simmonds, 2010, Lohmann et al., 1999, Pietschmann et al., 2001, Imhof and Simmonds, 2010, Gottwein et al., 2009). The replicon assay
-
Chronic exposure of cells to cytotoxic drugs
2021-09-16

Chronic exposure of cells to cytotoxic drugs can result in the selection of multiple phenotypic and genetic changes. Thus, the use of MCF7/VP cells, which were selected for resistance to VP-16, was potentially problematic. However, a thorough characterization of MCF7/VP cells demonstrated that they
-
After establishing improved GSNOR potency
2021-09-16

After establishing improved GSNOR potency, some of the potent inhibitors were further evaluated for microsomal stability and CYP inhibition studies (). Majority of the tested analogs revealed high metabolic stability in human and rat liver microsomes, and moderate to low stability in mouse liver mi
-
In addition to these effects on
2021-09-16

In addition to these effects on metabolic function in cardiac cells, this study also demonstrates changes in the expression of hypertrophic genes and proteins subsequent to GPR119 activation. Again this occurred in a distinct pattern dependent on palmitate exposure. Of interest SOCS3 mRNAs were decr
-
Gefitinib hydrochloride Typically upon chronic agonist expos
2021-09-16

Typically, upon chronic agonist exposure GPCRs undergo desensitization and internalization resulting in a loss of receptor responsiveness over time (Drake et al., 2006, Kelly et al., 2008). However, not all GPCR systems conform to this model of acute agonist-mediated regulation. Some receptors have
-
br Introduction Few decades after of HIV AIDS diagnosis it
2021-09-16

Introduction Few decades after of HIV/AIDS diagnosis, it has been still a health problem and impact will continue in the next decades. In 2015, HIV/AIDS was the 12th cause of death in the world and it's estimated that 1.2 million people was died of HIV/AIDS this year. In the global epidemiologica
-
br The GLI code The GLI code model
2021-09-16

The GLI code The GLI code model [21], [22] considers the total GLI function as a balance of positive activator (GLIA) and negative repressive (GLIR) activities with GLI1 being mostly a positive transcription factor and GLI3 mostly a transcriptional repressor. The GLIA:GLIR ratio is thus critical,
-
br Voltage dependent anion channel VDAC
2021-09-16

Voltage-dependent anion channel VDAC is a ubiquitous protein showing well conserved structural and functional properties in spite of major variations in its sequence (for review see [50]). Most of what we know about VDAC electrophysiological properties (for reviews, see [51], [52]) was initially
-
The typical pharmacophore for GPR agonists contains
2021-09-15

The typical pharmacophore for GPR40 agonists contains four parts: head (acid moiety), central (phenyl ring), linker and tail (aromatic carbocyclic or heterocyclic ring) [20]. On the other hand, the chemical features that are required for the PPARγ agonists include hydrogen bond donors and acceptors
16352 records 595/1091 page Previous Next First page 上5页 591592593594595 下5页 Last page